However, the sensitivity and specificity of determining HER2 status in metastases using tumour-to-spleen ratios (83% and 100%, respectively; a cut-off value of 4.7) were better than the sensitivity and specificity using [89Zr]-trastuzumab-PET for extrahepatic lesions (per-patient basis) calculated using SUVmax (75.8% and 61.5%, respectively; cut-off value of 3.2) [35]. Here, ERBB2 is linked to neoplasm.